Filing Details
- Accession Number:
- 0000899243-22-018610
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-18 16:21:29
- Reporting Period:
- 2022-05-16
- Accepted Time:
- 2022-05-18 16:21:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-05-16 | 11 | $246.21 | 64,882 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 10 | $247.95 | 64,872 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 20 | $249.35 | 64,852 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 32 | $250.78 | 64,820 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 10 | $251.43 | 64,810 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 10 | $252.66 | 64,800 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-16 | 40 | $254.19 | 64,760 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $246.21 (range $245.78 to $246.25).
- Open market sales reported on this line occurred at a weighted average price of $249.35 (range $249.24 to $249.45).
- Open market sales reported on this line occurred at a weighted average price of $250.78 (range $250.35 to $250.97).
- Open market sales reported on this line occurred at a weighted average price of $254.19 (range $253.74 to $254.57).
Billionaire Hedge Funds
